ISNES, Belgium, Nov. 10, 2017 /PRNewswire/ -- Singapore Volition
Pte. Ltd, a wholly-owned subsidiary of VolitionRx
Limited (NYSE American: VNRX) ("Volition"), has entered into a
Memorandum of Understanding ("MOU") with the National Taiwan
University ("NTU") to conduct two large colorectal cancer (CRC)
research studies across the Asia Pacific Region, totaling
approximately 7,000 patient samples. Subject to agreement on the
terms and conditions, the Parties intend to sign a binding CRC
Study Agreement in the first quarter of 2018.
"The signing of this MOU is a good start for Volition in the
Asia Pacific Region" commented Dr. Jasmine
Kway, Volition's Vice President of Asia. "We are
fortunate and delighted to be working with a renowned institution
and Professor Han-Mo Chiu, a
prominent thought leader. This large-scale study will be low cost
in line with Volition's other great value studies such as the
13,500-subject study in the U.S. and the ongoing 30,000-subject
prospective study in Europe and
demonstrates our commitment to conducting large trials worldwide to
drive the acceptance of our products."
The first trial will be a large scale multi-country,
multi-center and multi-ethnic study in the Asia Pacific Region,
including 5,000 asymptomatic colorectal cancer screening subjects.
The second trial will include up to 2,000 symptomatic colorectal
cancer patients. These studies are being conducted to test and
validate Volition's proprietary Nu.QTM platform for the
detection and diagnosis of colorectal cancer for marketing, rather
than for regulatory purposes.
The studies will be under the supervision of Professor
Han-Mo Chiu, Clinical Professor,
Department of Internal Medicine of NTU who will be the Principal
Investigator for both trials. Prof. Chiu is highly regarded and
widely published in this field, with many awards and achievements
to his name. Professor Chiu commented, "The early detection of
colorectal cancer could benefit the survival rate of patients
significantly. There is a clear need for a product which not only
has high accuracy but is also easy to use and affordable. I look
forward to proceeding with the collaboration with Volition on these
projects."
About the National Taiwan University
NTU is one of the most prestigious universities in the world and
is the top university in Taiwan.
The University has a wide network of partners and collaborators and
plays a leading role in education and research. The University has
four university level research centers, with an overall student
population of 33,000.
About Volition
Volition is a multi-national life sciences company developing
simple, easy to use blood-based cancer tests to accurately diagnose
a range of cancers. The tests are based on the science of
Nucleosomics®, which is the practice of identifying and
measuring nucleosomes in the bloodstream or other bodily fluid - an
indication that disease is present.
As cancer screening programs become more widespread, Volition's
products aim to help to diagnose a range of cancers quickly,
simply, accurately and cost effectively. Early diagnosis has the
potential to not only prolong the life of patients, but also to
improve their quality of life.
Volition's research and development activities are currently
centered in Belgium, with
additional offices in London,
Texas and Singapore, as the
company focuses on bringing its diagnostic products to market first
in Europe, then in the U.S. and
ultimately, worldwide.
For more information about Volition, visit Volition's website
(http://www.volitionrx.com) or connect with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn:
https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition's website address, Twitter,
LinkedIn, Facebook, and YouTube are not incorporated by reference
into this document and should not be considered part of this
document. The addresses for Volition's website, Twitter,
LinkedIn, Facebook, and YouTube are included in this document as
inactive textual references only.
Media / Investor Contacts
Louise Day,
Volition
L.day@volitionrx.com
+44 (0)7557
774620
|
Scott Powell,
Volition
S.powell@volitionrx.com
+1 (646) 650
1351
|
Tirth Patel,
Edison Advisors
tpatel@edisongroup.com
+1 (646) 653
7035
|
Rachel Carroll,
Edison Advisors
rcarroll@edisongroup.com
+44 (0)20 3077
5711
|
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to the effectiveness of Volition's bodily-fluid-based diagnostic
tests as well as Volition's ability to develop and successfully
commercialize such test platforms for early detection of cancer.
Volition's actual results may differ materially from those
indicated in these forward-looking statements due to numerous risks
and uncertainties. For instance, if Volition fails to develop and
commercialize diagnostic products, it may be unable to execute its
plan of operations. Other risks and uncertainties include
Volition's failure to obtain necessary regulatory clearances or
approvals to distribute and market future products in the clinical
IVD market; a failure by the marketplace to accept the products in
Volition's development pipeline or any other diagnostic products
Volition might develop; Volition will face fierce competition and
Volition's intended products may become obsolete due to the highly
competitive nature of the diagnostics market and its rapid
technological change; and other risks identified in Volition's most
recent Annual Report on Form 10-K and Quarterly Reports on Form
10-Q, as well as other documents that Volition files with the
Securities and Exchange Commission. These statements are based on
current expectations, estimates and projections about Volition's
business based, in part, on assumptions made by management. These
statements are not guarantees of future performance and involve
risks, uncertainties and assumptions that are difficult to predict.
Forward-looking statements are made as of the date of this release,
and, except as required by law, Volition does not undertake an
obligation to update its forward-looking statements to reflect
future events or circumstances.
Nucleosomics®, NuQ®, Nu.QTM and
HyperGenomics® and their respective logos are trademarks
and/or service marks of VolitionRx Limited and its subsidiaries.
All other trademarks, service marks and trade names referred to in
this press release are the property of their respective owners.
View original
content:http://www.prnewswire.com/news-releases/singapore-volition-signs-memorandum-of-understanding-with-the-national-taiwan-university-to-conduct-two-large-clinical-studies-300553770.html
SOURCE VolitionRx Ltd